News & Events

VivaQuant Releases AE-1010 Rhythm ExpressTM Software

March 7, 2017

VivaQuant announces the release of AE-1010 Rhythm Express Interval and Arrhythmia Analysis Software for use in research applications. Read more >

VivaQuant Celebrates Eight Years of Success

February 9, 2017

VivaQuant is celebrating eight years since its founding in 2009. Highlights from those eight years include... Read more >

VivaQuant's First 510(k) Filing Accepted by FDA

February 2017

VivaQuant is proud to announce that the U.S. FDA has accepted for review its 510(k) premarket notification for the HS-1 Rhythm Express Interval and Arrhythmia Analysis Software. Read more >

VivaQuant Profiled in CEOCFO Magazine

February 2016

CEOCFO Magazine interviewed VivaQuant CEO Brian Brockway about the company’s technology. Read more (external link) >

VivaQuant Awarded SBIR Grant

January 2016

The National Institutes of Health has awarded a Phase II SBIR grant to VivaQuant for development of a comfortable, accurate, and efficient wearable device for patients with atrial fibrillation. Read more >

Learn how ECG restitution analysis can assess cardiac stress and arrhythmia vulnerability

May 2015

Watch this webinar to learn how ECG restitution analysis, enabled by VivaQuant technology, can help you assess cardiac safety. Access to this link provided courtesy of the Safety Pharmacology Society. Read more (external link) >

VivaQuant CEO and DSITM founder Brian Brockway presents the history of biotelemetry

May 2014

Availability of implantable biotelemetry has played an important role in drug development and biomedical research. This technology has resulted in vastly improved information from research studies and has greatly contributed to reduction and refinement of laboratory animals used in research. Brian Brockway discusses the history of the field and how DSITM came to play a key role in democratizing the use of implantable biotelemetry in research.

DSI is a registered trademark of Data Sciences International.

VivaQuant receives patent award for technique to remove in-band noise from ECGs without distorting morphology

February 2014

Removing in-band noise while preserving ECG morphology enables significantly increased arrhythmia detection accuracy and interval measurement consistency. These anticipated improvements have indeed been achieved through an implementation of this invention whereby in-band noise have been reduced by 26 dB while preserving ECG morphology. Read more (external link) >

VivaQuant profiled by Mathworks for best practices in embedded code development

March 2014

CTO Dr. Marina Brockway has led VivaQuant’s efforts to develop an efficient and robust process for turning complex signal processing algorithms developed on Matlab into embedded code for efficient execution on an ARM Cortex microcomputing platform. Mathworks profiled VivaQuant’s success in this endeavor in their newsletter, culminating with an invited presentation by Dr. Brockway at the Mathworks North American user group.

VivaQuant Accelerates Development and Validation of Embedded Device for Ambulatory ECG Testing [external link]

VivaQuant wins Drug Safety Council Technology Innovation Award

June 2011

VivaQuant was presented with this prestigious award in recognition of the potential of its MDSP ECG processing technology to improve decision making in cardiac safety assessment of new drugs. Read more (external link) >
© 2017 VivaQuant, LLC | Sitemap